A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Recruiting
Observational Study
Multiple Sclerosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Female
- Study type
- Observational
- Participants needed
- 1,182 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of Multiple sclerosis (MS)
* Currently or recently pregnant
* Reside in the United States, Canada or Germany.
Exclusion Criteria:
• Exposure to other S1P therapies, cladribine, or mitoxantrone during the first trimester.
Other protocol-defined inclusion/exclusion …
Contacts
BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
CONTACT
First line of the email MUST contain the NCT# and Site #.
CONTACT